Neupro (Rotigotine)

Rotigotine, the active ingredient in Neupro, is a dopamine agonist (non‑ergot) presented as a transdermal patch for transdermal use. It is indicated for the management of Parkinson's disease and Restless Legs Syndrome in adult patients. GNH USA supplies Neupro as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Neupro is a dopamine agonist used in movement‑disorder therapy. It provides symptomatic relief by stimulating central dopamine receptors. - Parkinson's disease: improves motor function and reduces rigidity and bradykinesia. - Restless Legs Syndrome: lessens the urge to move the legs and improves sleep quality. - Motor fluctuations in Parkinson's disease: smooths on/off periods and reduces wearing‑off phenomena.

Rotigotine may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Application site reaction: erythema, pruritus or edema at the patch site. - Nausea: mild to moderate gastrointestinal upset. - Dizziness: sensation of light‑headedness, especially on standing. - Insomnia: difficulty initiating or maintaining sleep.

Serious or Rare Side Effects: - Hallucinations: visual or auditory disturbances requiring medical review. - Impulse control disorders: compulsive gambling, shopping or eating. - Severe skin reactions: bullous dermatitis or Stevens‑Johnson‑like eruptions.

Before initiating Rotigotine therapy, consider the following safety measures. - Dose titration: start with the lowest patch strength and increase as directed by the prescriber. - Cardiovascular monitoring: observe blood pressure and orthostatic changes, especially in elderly patients. - Psychiatric assessment: watch for new or worsening hallucinations, mood swings or suicidal thoughts. - Skin inspection: regularly examine the patch site for irritation or allergic signs. - Pregnancy and lactation: safety has not been established; avoid use unless clearly needed. - Store at room temperature: keep in the original pouch, protect from light and moisture.

Rotigotine can interact with several drug classes; awareness helps prevent adverse outcomes.

Major Interactions (Avoid): - MAO‑B inhibitors: may potentiate dopaminergic effects and increase risk of hypertensive crisis. - Antipsychotics: dopamine antagonists can reduce Rotigotine efficacy and precipitate worsening of Parkinsonian symptoms.

Moderate Interactions (Monitor Closely): - Strong CYP1A2 inhibitors (e.g., fluvoxamine): may increase Rotigotine plasma levels. - Strong CYP2C19 inhibitors (e.g., omeprazole): may elevate exposure and side‑effect risk. - Antihypertensive agents: additive blood‑pressure lowering effect may cause symptomatic hypotension.